Monday, 5 December, 2022
TopicOxford vaccine

Topic: Oxford vaccine

Oxford trial ‘lousy’, we’ll be ready with 70 cr Covaxin doses this year, says Bharat Biotech

Bharat Biotech MD Dr Krishna Ella says they gave ‘excellent safety data tested on around 25,000 participants’ & their efficacy data will be available by February-March.

Oxford vaccine to cost Rs 219-292 to govt, double for private buyers, says Adar Poonawalla

The Serum Institute of India CEO said Covishield will be sold to the govt and Global Alliance for Vaccines and Immunization countries first and on the private market later.

UK set to give first Oxford Covid vaccine shots as cases surge

Britain is recording more than 50,000 new cases daily, with the new strain that’s estimated to be as much as 70% more transmissible fueling the pandemic’s resurgence.

UK approves AstraZeneca-Oxford Covid vaccine for emergency use

The vaccine will be prioritised for the country’s most vulnerable groups. It’s the second Covid vaccine to be cleared for emergency use in the UK after Pfizer and BioNTech.

Oxford-AstraZeneca vaccine has 70% efficacy against Covid, interim results in Lancet reveal

The findings, published The Lancet, are the first full peer-reviewed efficacy results to be published for a Covid-19 vaccine.

Approval, pricing, distribution — 5 questions India faces before rolling out Covid vaccine

3 firms have applied for emergency use approval, but no clarity yet on if people will get to choose a vaccine, or what the state’s role in procurement will be.

UK asks regulator to approve Oxford-AstraZeneca vaccine for temporary supply

If authorised, the UK will be one of the first countries in the world to receive the vaccine. AstraZeneca expects to have up to 4 million doses ready by the end of 2020.

AstraZeneca plans another Covid vaccine trial to clear uncertainty and confusion

Questions are mounting over AstraZeneca vaccine after it said a lower dosage level that appeared more effective resulted from a manufacturing discrepancy.

India’s vaccine delivery roadmap and Allahabad HC’s history of ‘landmark’ verdicts

The best cartoons of the day, chosen by the editors at ThePrint.

AstraZeneca Covid vaccine’s 90% efficacy came in younger trial group

The vaccine was 90% effective when a half-dose was given before a full-dose booster. However, that regime was administered to participants in a group whose age was capped at 55.

On Camera

YourTurn

File photo | People's Liberation Army of China during a military parade | Wikimedia Commons/kremlin.ru

China’s military power is catching up with its economic might. New era is indeed one of war

China faces the possibility that its first war against Taiwan or India could potentially lead many others to come together with the US, and form a tighter military alliance against it.
Representational Image.| Pixabay

Rupee to hover near weaker side of 81/dollar, bond yields await RBI’s monetary policy decision

The rupee ended last week at 81.3175 per dollar but underperformed its Asian peers due to strong demand for the greenback from corporates.

Defence

Russian President Vladimir Putin with Chinese President Xi Jinping. (Photo Credit - Reuters)

In western arms sanctions on Russia, China’s arms industry could stand to gain

The arms export embargoes on Moscow could create an opportunity for Beijing to supply arms to countries like Myanmar, which are heavily dependent on Russian arms.
Illustration: Soham Sen | ThePrint

Gujarat election is anything but dull. BJP’s political neurosis about AAP is the hidden headline

Gujarat is the only state where Modi is directly in contention. Even if he wins, the team that runs him closest has much to gain.